Carvista
Generic Name
Cargrelor
Manufacturer
Hypothetical Pharma Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| carvista 125 mg tablet | ৳ 5.00 | ৳ 50.00 |
Description
Overview of the medicine
Carvista 125 mg Tablet is an antiplatelet medication containing Cargrelor, used to prevent blood clots in patients at risk of atherothrombotic events such as myocardial infarction, stroke, or established peripheral arterial disease. It works by inhibiting platelet aggregation.
Uses & Indications
Dosage
Adults
The usual recommended dose is 125 mg orally once daily, with or without food. For Acute Coronary Syndrome, a loading dose of 300 mg may be given, followed by 125 mg once daily.
Elderly
No specific dose adjustment is generally required in elderly patients, but caution should be exercised due to increased risk of bleeding.
Renal_impairment
No dose adjustment is needed for mild to moderate renal impairment. Use with caution in severe renal impairment (CrCl <30 mL/min) due to limited data.
How to Take
Carvista 125 mg Tablet should be taken orally, once daily, with or without food. Swallow the tablet whole with a glass of water. Do not crush or chew it.
Mechanism of Action
Cargrelor selectively and irreversibly inhibits the binding of adenosine diphosphate (ADP) to its P2Y12 receptor on platelets. This inhibition prevents the activation of the GPIIb/IIIa complex, thereby inhibiting platelet aggregation and the formation of blood clots.
Pharmacokinetics
Onset
Platelet inhibition starts within 2-4 hours, with maximal effect observed within 3-7 days of consistent dosing.
Excretion
Primarily excreted via urine (approximately 50%) and feces (approximately 45%) as metabolites.
Half life
The active metabolite has a plasma half-life of approximately 6-8 hours, but the antiplatelet effect lasts longer due to irreversible binding.
Absorption
Rapidly and extensively absorbed from the gastrointestinal tract following oral administration. Bioavailability is high, but can be affected by food.
Metabolism
Extensively metabolized in the liver, primarily by cytochrome P450 enzymes (e.g., CYP2C19, CYP3A4), to its active metabolite and inactive metabolites.
Side Effects
Contraindications
- Hypersensitivity to the active substance Cargrelor or any component of the tablet.
- Active pathological bleeding, such as peptic ulcer or intracranial hemorrhage.
- Severe hepatic impairment.
- Concomitant use with strong CYP2C19 inhibitors in certain patient populations.
Drug Interactions
Warfarin and other Oral Anticoagulants
Significantly increased risk of bleeding. Concomitant use is generally not recommended.
Heparin and other Parenteral Anticoagulants
Increased risk of bleeding. Close monitoring is advised.
NSAIDs (Nonsteroidal Anti-inflammatory Drugs)
Increased risk of gastrointestinal bleeding. Use with caution.
CYP3A4 Inducers (e.g., Rifampicin, Carbamazepine, Phenytoin)
May reduce the plasma concentration of Cargrelor's active metabolite, potentially decreasing its antiplatelet effect.
CYP2C19 Inhibitors (e.g., Omeprazole, Esomeprazole, Fluoxetine, Fluvoxamine, Ticlopidine)
May reduce the efficacy of Cargrelor by inhibiting its conversion to the active metabolite. Concomitant use should be avoided or carefully monitored.
Storage
Store in a cool, dry place below 30°C. Protect from light and moisture. Keep out of reach of children.
Overdose
Symptoms of overdose may include prolonged bleeding time and subsequent bleeding complications. In case of suspected overdose, seek immediate medical attention. Management is supportive, and platelet transfusions may be considered if bleeding is severe and requires rapid reversal of antiplatelet effects.
Pregnancy & Lactation
Pregnancy: Cargrelor is not recommended during pregnancy unless absolutely necessary. Animal studies have shown reproductive toxicity. Lactation: It is unknown whether Cargrelor or its metabolites are excreted in human milk. Breastfeeding is not recommended during treatment with Carvista.
Side Effects
Contraindications
- Hypersensitivity to the active substance Cargrelor or any component of the tablet.
- Active pathological bleeding, such as peptic ulcer or intracranial hemorrhage.
- Severe hepatic impairment.
- Concomitant use with strong CYP2C19 inhibitors in certain patient populations.
Drug Interactions
Warfarin and other Oral Anticoagulants
Significantly increased risk of bleeding. Concomitant use is generally not recommended.
Heparin and other Parenteral Anticoagulants
Increased risk of bleeding. Close monitoring is advised.
NSAIDs (Nonsteroidal Anti-inflammatory Drugs)
Increased risk of gastrointestinal bleeding. Use with caution.
CYP3A4 Inducers (e.g., Rifampicin, Carbamazepine, Phenytoin)
May reduce the plasma concentration of Cargrelor's active metabolite, potentially decreasing its antiplatelet effect.
CYP2C19 Inhibitors (e.g., Omeprazole, Esomeprazole, Fluoxetine, Fluvoxamine, Ticlopidine)
May reduce the efficacy of Cargrelor by inhibiting its conversion to the active metabolite. Concomitant use should be avoided or carefully monitored.
Storage
Store in a cool, dry place below 30°C. Protect from light and moisture. Keep out of reach of children.
Overdose
Symptoms of overdose may include prolonged bleeding time and subsequent bleeding complications. In case of suspected overdose, seek immediate medical attention. Management is supportive, and platelet transfusions may be considered if bleeding is severe and requires rapid reversal of antiplatelet effects.
Pregnancy & Lactation
Pregnancy: Cargrelor is not recommended during pregnancy unless absolutely necessary. Animal studies have shown reproductive toxicity. Lactation: It is unknown whether Cargrelor or its metabolites are excreted in human milk. Breastfeeding is not recommended during treatment with Carvista.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24 months from the date of manufacture.
Availability
Pharmacies nationwide
Approval Status
Approved
Patent Status
Patent Pending
WHO Essential Medicine
YesClinical Trials
Clinical trials for Cargrelor have demonstrated its efficacy in reducing the incidence of major adverse cardiovascular events in patients with ACS and those undergoing PCI. Ongoing studies are evaluating its long-term safety and efficacy in various patient populations.
Lab Monitoring
- Complete Blood Count (CBC) with platelet count: Regularly monitor, especially if bleeding is suspected.
- Coagulation parameters (e.g., PT/INR, aPTT): If bleeding complications arise or before surgery.
- Liver function tests (LFTs): Periodically, especially in patients with pre-existing hepatic impairment.
Doctor Notes
- Advise patients about the increased risk of bleeding and instruct them to report any unusual bleeding promptly.
- Consider CYP2C19 genetic testing in patients with high thrombotic risk or those exhibiting suboptimal response to treatment.
- Review concomitant medications, especially other antithrombotic agents or strong CYP2C19 inhibitors, and adjust treatment as necessary.
Patient Guidelines
- Take Carvista exactly as prescribed by your doctor. Do not stop taking it without consulting your doctor, even if you feel well.
- Inform your doctor or dentist about taking Carvista before any surgery or dental procedure, as it increases the risk of bleeding.
- Report any unusual bleeding or bruising, such as nosebleeds, blood in urine/stools, or prolonged bleeding from cuts, to your doctor immediately.
Missed Dose Advice
If you miss a dose of Carvista, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and resume your regular dosing schedule. Do not double the dose to make up for a missed one.
Driving Precautions
Carvista is generally not expected to affect your ability to drive or operate machinery. However, if you experience dizziness or visual disturbances, you should avoid driving or operating machinery until these symptoms subside.
Lifestyle Advice
- Avoid activities that may increase your risk of bleeding or injury, such as contact sports or aggressive shaving.
- Limit or avoid alcohol consumption, as it may increase the risk of stomach bleeding.
- Maintain a healthy lifestyle, including a balanced diet and regular exercise, as advised by your healthcare provider.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Carvista Brand
Other medicines available under the same brand name
